Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rifaximin in Fatty Liver Disease (RiFL)

This study has been terminated.
(Review of primary endpoint data by study Investigators concluded no further patients required.)
National Health Service, United Kingdom
Information provided by (Responsible Party):
Imperial College London Identifier:
First received: May 17, 2011
Last updated: October 16, 2012
Last verified: October 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)